In recent years, Americans have shown a growing interest in psychedelics, particularly psilocybin-containing “magic mushrooms.” Despite this rising trend in use, a new body of research suggests that emergency and hospital admissions related to these substances remain surprisingly low, especially when compared to alcohol and opioids.
The Psychedelic Renaissance and Rising Use
Psychedelic substances, once relegated to counterculture movements of the 1960s, are experiencing a renaissance in the United States. This resurgence is largely driven by growing scientific interest in their therapeutic potential for treating mental health conditions like depression, PTSD, and anxiety.
Law enforcement data reveals a dramatic increase in psilocybin mushroom seizures between 2017 and 2022, suggesting a significant uptick in availability and use. 1 This trend aligns with broader cultural shifts, as several states have moved toward decriminalizing or legalizing psilocybin for therapeutic use.
Hospital Admissions: A Surprising Disparity
Despite the increase in psychedelic use, hospital admissions tell a different story. Recent research indicates that hallucinogen-related emergency department visits and hospital admissions remain relatively rare compared to other substances.
A 2024 study published in JAMA Network Open examined hallucinogen-related emergency department and hospital admissions from 2016 to 2023. While the exact numbers are elusive due to access issues with the full study, findings suggest that hallucinogens account for only 0.6-1.2% of substance-related hospital encounters. 2
In stark contrast, alcohol continues to dominate substance-related hospital admissions, with rates increasing from approximately 48% to nearly 60%. Opioids, while showing some decline in recent years, still represent a significant portion of substance-related hospitalizations. 3
Putting the Numbers in Perspective
- Hallucinogens: 0.6-1.2% of substance-related hospital encounters
- Alcohol: Up to 60% of substance-related hospital encounters
- Opioids: Significant percentage (exact figures vary by year and source)
This data suggests that the acute public health burden of hallucinogens is relatively low compared to alcohol and opioids, challenging common assumptions about the relative risks of different substances.
Therapeutic Potential and Changing Perceptions
The growing interest in psychedelics isn’t just about recreational use. There’s a serious scientific effort underway to understand their therapeutic potential. The U.S. Food and Drug Administration has granted psilocybin breakthrough therapy designation for treatment-resistant depression (2018) and major depressive disorder (2019), recognizing its potential to address significant unmet medical needs. 4
With over 130 clinical trials currently listed on ClinicalTrials.gov, researchers are investigating psilocybin’s effectiveness for a range of conditions. 5 This surge in research interest reflects a broader shift in how both the medical community and the public view these substances.
Implications for Public Health and Policy
The stark contrast between rising use and low hospital admissions has important implications for public health policy. As states continue to consider decriminalization and therapeutic use programs, this data provides valuable context.
The findings suggest that while alcohol and opioids remain the primary drivers of substance-related hospitalizations, psychedelics pose a relatively low acute risk. However, this doesn’t mean they’re without risk – proper medical supervision and careful attention to set and setting remain crucial for safe use.
As our understanding of these substances evolves, policymakers face the challenge of creating frameworks that acknowledge both the risks and benefits. The low hospital admission rates for psychedelics, combined with their therapeutic potential, suggest that current classification systems may need reevaluation.
Conclusion
The story of psychedelics in America today is one of complexity and contradiction. As use increases dramatically, hospital admissions remain surprisingly low. Meanwhile, scientific research continues to reveal promising therapeutic applications for conditions that have proven difficult to treat with conventional approaches.
This emerging data challenges long-held assumptions about the relative dangers of different substances and highlights the need for evidence-based drug policies. As we move forward, balancing public safety with the potential benefits of these substances will require careful attention to both scientific evidence and public health outcomes.
The psychedelic renaissance isn’t just about changing laws or cultural attitudes – it’s about developing a more nuanced understanding of substance-related risks and benefits. In this context, the relatively low hospital admission rates for hallucinogens provide an important data point that deserves serious consideration in ongoing policy discussions.
Sources
- NIDA: Law enforcement seizures of psilocybin mushrooms rose dramatically between 2017-2022
- Medical Xpress: Psychedelic decriminalization hasn’t increased ER visits
- Psypost: Rising psychedelic use has not led to corresponding surge in hospital admissions
- Third Wave: FDA Breakthrough Therapy Designation to Psilocybin Therapy
- PMC: The Promise of Therapeutic Psilocybin
- JAMA Network Open: Trends in Hallucinogen-Related Emergency Department and Hospital Admissions, 2016 to 2023
Leave a Reply